Outcome of treatment of adult acute lymphoblastic leukemia with hyperfractionated cyclophosphamide, doxorubicin, vincristine, dexamethasone/methotrexate, cytarabine: results from an Australian population-Reference-Cited by-同舟云学术

Outcome of treatment of adult acute lymphoblastic leukemia with hyperfractionated cyclophosphamide, doxorubicin, vincristine, dexamethasone/methotrexate, cytarabine: results from an Australian population

Published:2010-12-06 Issue:1 Volume:52 Page:85-91
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Morris Kirk,Weston Helen,Mollee Peter,Marlton Paula,Gill Devinder,Kennedy Glen

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

http://www.tandfonline.com/doi/pdf/10.3109/10428194.2010.532889

Reference22 articles.

1. Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia

2. Results of Treatment With Hyper-CVAD, a Dose-Intensive Regimen, in Adult Acute Lymphocytic Leukemia

3. Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate

4. Outcome of treatment with Hyper-CVAD regimen in Chinese patients with acute lymphocytic leukemia

5. Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prognostic Factors and Outcome of Patients with Adult Acute Lymphoblastic Leukemia Treated with the Hyper-CVAD Regimen: A Retrospective Study;Advances in Hematology;2023-11-09

2. CD20, generalidades básicas-moleculares y su posible relación como marcador de mal pronóstico en leucemia;Revista Colombiana de Cancerología;2023-03-30

3. Higher Survival Advantage With Hyper-CVAD Chemotherapy Regimen Before Allogeneic Stem Cell Transplantation In Patients With High Risk Adult Acute Lymphoblastic Leukemia: Two-Center Experience;Muğla Sıtkı Koçman Üniversitesi Tıp Dergisi;2022-08-20

4. Clinical experience with frontline Hyper-CVAD-based regimens, including Hyper-CVAD plus ponatinib, in patients with acute lymphoblastic leukemia treated at a comprehensive cancer center;Leukemia Research;2022-08

5. An effective nanoparticles for drug delivery system;Materials Today: Proceedings;2022